Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Gastroenterology
Disease Category: Colon Cancer
Trial Information
A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer
The primary objective of this study is to estimate the treatment effect on progression-free survival (PFS) of panitumumab relative to bevacizumab in combination with mFOLFOX6 chemotherapy as first-line therapy in subjects with tumors expressing wild-type KRAS, unresectable mCRC.
Patient Inclusion Criteria:
- Subjects with at least 1 uni-dimensionally measurable lesion of at least 20mm per modified RECIST guidelines
- Wild-type KRAS tumor status
- Adequate hematologic, renal, hepatic, metabolic, and coagulation function
- Prior chemotherapy or other systemic anticancer therapy for treatment of metastatic colorectal carcinoma
- Clinically significant cardiac disease
- Recent pulmonary embolism, deep vein thrombosis, or other significant venous event
Cathy Spears, Research Manager
St. Francis Hospital and Health Centers
1500 N Albany Street, Suite 1001
Beech Grove, IN 46107
Phone: 317-782-7819
Fax: 317-782-7828
EMail: cathy.spears@ssfhs.org
View Google Map
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
